Table 1 Summary of data on rates of resistant Pseudomonas aeruginosa
Author (Year) | Country | Setting | Rates of resistance | Ref. |
|---|---|---|---|---|
NNIS (2004) | USA | ICU | Imipenem resistance = 15% | [18] |
Quinolone resistance = 9% | ||||
3rd-generation cephalosporin resistance = 20% | ||||
Obritsch et al. (2004) | USA | ICU | MDR P. aeruginosa (defined as resistance to at least three of the following four drugs: imipenem, ceftazidime, ciprofloxacin, and tobramycin) increased from 4% in 1993 to 14% in 2002 | [19] |
Morrow et al. (2013) | USA | Tertiary | Doripenem resistance = 11.4% | [20] |
Imipenem resistance = 21.9% | ||||
Meropenem resistance = 15.4% | ||||
Levofloxacin resistance = 26.0% | ||||
Ceftazidime resistance = 15.2% | ||||
Tobramycin resistance = 10.1% | ||||
Piperacillin / tazobactam resistance = 14.7% | ||||
Souli et al. (2008), European Center for Disease Prevention and Control (2013) | Europe | Tertiary | Carbapenem resistance = > 25% | |
De Francesco et al. (2013) | Italy | Tertiary | MDR P. aeruginosa (defined as resistance to 5 commonly prescribed antibiotics) increased from 2.1% in 2007 to 4.1% in 2010 | [23] |
Joo et al. (2011) | Korea | Tertiary | Ceftazidime resistance = 37% | [24] |
Piperacillin resistance = 22% | ||||
Imipenem resistance = 23% | ||||
Fluoroquinolone resistance = 24% | ||||
Aminoglycoside resistance = 18% | ||||
Gales et al. (2001) | South America | Tertiary | MDR resistance = 8.2% | [25] |
Raja et al. (2001) | Malaysia | Tertiary | MDR resistance = 6.9% | [26] |